FBN1 and Obesity: Clinical studies have strongly associated circulating asprosin levels with disease severity in conditions such as obesity, MASLD, and other obesity‐related cardiometabolic conditions.[33, 34] By studying MASLD patients and mice, we confirm that plasma asprosin levels are positively correlated with markers of liver injury as well as TC and TG.